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Stephanie M. Willerth a, Allison Rader a, Shelly E. Sakiyama-Elbert a,b,*a Department of Biomedical Engineering, Washington University, St. Louis, MO 63130, USA
b Center for Materials Innovation, Washington University, St. Louis, MO 63130, USAReceived 14 January 2008; received in revised form 23 May 2008; accepted 29 May 2008Abstract The goal of this project was to develop 3-D biomaterial scaffolds that present cues to direct the differentiation of
embryonic stem (ES) cell-derived neural progenitor cells, seeded inside the scaffolds, into mature neural phenotypes,
specifically neurons and oligodendrocytes. Release studies were performed to determine the appropriate conditions for
retention of neurotrophin-3 (NT-3), sonic hedgehog, and platelet-derived growth factor (PDGF) by an affinity-based delivery
system incorporated into fibrin scaffolds. Embryoid bodies containing neural progenitors were formed frommouse ES cells, using
a 4−/4+ retinoic acid treatment protocol, and then seeded inside fibrin scaffolds containing the drug delivery system. This
delivery system was used to deliver various growth factor doses and combinations to the cells seeded inside the scaffolds.
Controlled delivery of NT-3 and PDGF simultaneously increased the fraction of neural progenitors, neurons, and
oligodendrocytes while decreasing the fraction of astrocytes obtained compared to control cultures seeded inside unmodified
fibrin scaffolds with no growth factors present in the medium. These results demonstrate that such a strategy can be used to
generate an engineered tissue for the potential treatment of spinal cord injury and could be extended to the study of
differentiation in other tissues.
© 2008 Elsevier B.V. All rights reserved.Introduction
Combining bioactive scaffolds with embryonic stem (ES) cells
provides a desirable alternative for replacement of damaged
tissues (Ferreira et al., 2007; Levenberg et al., 2003, 2005;
Willerth et al., 2006, 2007a). For such engineered tissues to
function and integrate effectively in vivo, the cues necessary
for promoting optimal ES cell differentiation should be re-
tained inside such scaffolds, allowing them to be accessible
to the cells and preventing loss due to diffusion into the* Corresponding author. Department of Biomedical Engineering,
Washington University, St. Louis, MO 63130, USA. Fax: +1 314 935 7448.
E-mail address: sakiyama@wustl.edu (S.E. Sakiyama-Elbert).
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doi:10.1016/j.scr.2008.05.006surrounding tissue. One of the most commonly used methods
for incorporating growth factors or other cues involves cova-
lently tethering them to the scaffold material (Beckstead et
al., 2006; Fan et al., 2007; Gomez et al., 2007; Gomez and
Schmidt, 2007; Ho et al., 2007; Kuhl and Griffith-Cima, 1996;
Taqvi et al., 2006; Yim and Leong, 2005). These methods
have been previously used to promote ES cell differentiation
and survival (Beckstead et al., 2006; Ho et al., 2007; Taqvi et
al., 2006; Yim and Leong, 2005). While such strategies are
highly effective at retaining such cues inside scaffolds, cova-
lent linkages can impede internalization and, in turn, affect
the activity and function of growth factors. Affinity-based
delivery systems have been explored as alternative methods
of retaining growth factors inside scaffolds via noncovalent
interactions (Benoit and Anseth, 2005; Benoit et al., 2007;.
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Taylor et al., 2004, 2006; Taylor and Sakiyama-Elbert, 2006;
Wissink et al., 2001). These systems utilize the interaction
between heparin and a target drug to retain the drug inside a
scaffold, mimicking the way the extracellular matrix
sequesters growth factors in vivo. These systems improve
the retention of growth factor activity and allow growth
factor internalization. Such biomimetic delivery systems
have shown promise as a potential treatment for spinal cord
injury (SCI), but these scaffolds alone are not sufficient to
produce functional recovery (Taylor et al., 2004, 2006; Taylor
and Sakiyama-Elbert, 2006).
The use of progenitor cells derived fromES cells as ameans
of restoring cellular populations lost because of SCI has also
been investigated with some promising results (Keirstead et
al., 2005; Liu et al., 2000; McDonald et al., 1999; Nistor et al.,
2005). In a study by McDonald et al., mouse ES cells were
induced to form embryonic stem cell-derived neural lineage
precursor cells (ESNPCs) using the 4−/4+ retinoic acid treat-
ment protocol (Bain et al., 1995) and then injected into a rat
model of SCI as treatment (McDonald et al., 1999). These cells
promoted a modest increase in functional recovery (∼3 on
the Basso, Beattie, and Bresnahan scale). However, few cells
(∼5k) differentiated into neurons and the viability of the
transplanted cells was low (∼10k). Similar results have been
obtained by other groups when stem cells were transplanted
directly in the injured spinal cord (Cao et al., 2001, 2002).
The glial scar promotes differentiation of stem cells into glia
and discourages cell migration into the injury site. Implan-
table biomimetic scaffolds could provide a permissive
microenvironment for transplanted stem cells and cues to
promote survival and differentiation into neurons and
oligodendrocytes at the injury site.
Toward this goal, previous work from our lab has iden-
tified the appropriate conditions for culturing mouse ESNPCs
inside three-dimensional fibrin scaffolds and soluble growth
factors that promote the differentiation of ESNPCs into
neurons and oligodendrocytes (Willerth et al., 2006, 2007a).
The later study found that combining neurotrophin-3 (NT-3)
with platelet-derived growth factor (PDGF) and NT-3 with
sonic hedgehog (Shh) increased the fraction of ESNPCs that
differentiated into neurons and oligodendrocytes compared
to control cultures in unmodified fibrin with no growth fac-
tors present in the medium, making them worthy of further
investigation for use with our affinity-based delivery system.
Additionally, these growth factors have shown beneficial
effects when tested in the context of SCI. Delivery of NT-3
has been shown to enhance neural fiber sprouting into the
injury site (Taylor et al. 2004, 2006) and promote regenera-
tion of the corticospinal tract (Schnell et al., 1994; Taylor et
al., 2004, 2006; Tuszynski et al., 2003). Treatment with all
three PDGF isoforms (PDGF-AA, PDGF-AB, and PDGF-BB) pro-
motes angiogenesis to the injury site, which may help
produce a more hospitable environment for regeneration to
occur (Hiraizumi et al., 1992, 1993, 1996). Shh induces
proliferation of neural progenitors when applied after SCI,
and when used in combination with transplanted oligoden-
drocyte progenitor cells, it has been shown to improve reco-
very and increase the amount of white matter spared from
injury (Bambakidis and Miller, 2004; Bambakidis et al., 2003).
Thus, these growth factors serve two purposes in vivo. They
can promote the differentiation of ESNPCs into neurons andoligodendrocytes while helping to improve the microenvir-
onment at the injury site, allowing for regeneration by the
spared host cells.
The goal of this work was to generate an optimized
scaffold for repair of SCI that contained an affinity-based
delivery system, growth factors, and ESNPCs. To achieve this
goal, delivery conditions for retention of NT-3, PDGF-AA, and
Shh were determined and then the ability of these factors to
direct the differentiation of ESNPCs seeded inside scaffolds
when presented by the delivery system was determined.
Once optimal doses for each growth factor were found, these
doses were tested in combination to determine their effec-
tiveness at promoting differentiation of the ESNPCs into
neurons and oligodendrocytes to serve as a replacement for
the tissue lost to SCI. Specifically, the goal was to determine
the doses of growth factor that needed to be presented by
the delivery system to replicate the differentiation observed
in the previous soluble growth factor studies (Willerth et al.,
2007a) that would allow presentation of similar cues follow-
ing cell transplantation. Additionally, control experiments
were performed to confirm that the effects observed were
due to the enhanced retention of growth factors by the
delivery system. These scaffolds could also be used to repli-
cate the microenvironment present during the different
stages of development and may have further applications for
studying the cues necessary to direct stem cell differentia-
tion for other lineages.
Results
Determining delivery system conditions for
maximum growth factor retention inside fibrin
scaffolds
To determine the delivery system conditions that would ge-
nerate the slowest release of the individual growth factors to
ESNPCs, two peptide-to-heparin ratios were tested in the
context of the delivery system by changing the concentration
of heparin present. Changing the heparin concentration also
alters the ratio of heparin to growth factor and all of these
ratios are listed in Table 1. The two chosen heparin con-
centrations (62.5 and 6.25 μM) resulted in either a 4:1 or a
40:1 heparin to peptide ratio, respectively. These ratios
were selected based on previous work (Taylor et al., 2004;
Wood and Sakiyama-Elbert, 2008) and had been shown to
provide sustained release of growth factors that possess an
affinity for heparin. The concentration of heparin changes
the number of binding sites available to the growth factor
present in the scaffold and thus affects the rate of growth
factor release from the scaffolds. The goal of this release
study was to determine which ratio resulted in the slowest
growth factor release from the scaffolds and retained the
maximum amount of growth factor. Release was evaluated
over a 2-week period, which corresponds roughly to the de-
gradation time of the fibrin scaffolds in vivo. Over the first
24 h, the scaffolds were washed extensively (five times) to
remove unincorporated components, followed by one wash a
day for the remaining 13 days of the study.
Figure 1A shows the results of the 14-day release study to
determine the optimal peptide-to-heparin ratio for NT-3
delivery. When no heparin was present, virtually all of the
Table 1 Ratios of the affinity-based delivery system components
Growth factor Peptide-to-
heparin ratio
Heparin-to-growth
factor ratio
Estimated fraction
of growth factor
bound a
Fraction of growth
factor retained in
scaffold after 24 h b
Fraction of growth
factor retained in
scaffold after 14 days b
Neurotrophin-3 4:1 1700:1 0.89 0.61 0.39
40:1 170:1 0.74 0.44 0.25
Platelet-derived
growth factor
4:1 1600:1 0.98 0.53 0.43
40:1 160:1 0.82 0.37 0.26
Sonic hedgehog 4:1 1300:1 0.74 0.19 0.10
40:1 130:1 0.64 0.02 0.01
a Estimated retention for one wash at equilibrium. Value estimated from dissociation constants.
b Obtained from release studies shown in Fig. 2.
207Stem cell differentiation inside fibrin scaffoldsNT-3 (∼99k) was released from the scaffold by the end of 14
days. In contrast, both the 4:1 and the 40:1 ratios provided
sustained NT-3 delivery over the same time period. The 4:1
peptide-to-heparin ratio retained the most NT-3 (∼40k) in
the scaffold at the end of the study, which was significantly
more than the amount retained when the 40:1 ratio was
used. The different ratios produced two different rates of
NT-3 release, with the 4:1 ratio being selected for delivery of
NT-3 to the ESNPCs seeded inside the scaffolds because it
generated the slowest release and maximized growth factor
retention.
Similar results were obtained for the release studies
involving delivery of PDGF (Fig. 1B). Three different rates of
release were observed, depending on the amount of heparin
present in the delivery system.When no heparin was present,
∼10k of the PDGF remained in the scaffold at the end of
the study. When a 4:1 ratio was used, ∼42k of the PDGF was
retained in the scaffold, while the 40:1 ratio resulted in
∼26k retention. Thus the 4:1 peptide-to-heparin ratio was
selected for the in vitro differentiation studies because it
retained significantly more PDGF than the 40:1 ratio.
Release of Shh from the delivery system was also char-
acterized for the different heparin-to-peptide ratios (Fig.
1C). The 4:1 ratio generated the slowest rate of release, but
it retained only ∼10k of Shh at the end of the 14-day study.
However, when no heparin was present or the 40:1 ratio was
used, Shh was released from the system much more rapidly,
with 99k of the Shh released by day 2 of the 14-day study.
This release rate was much faster than the rate observed for
the scaffolds containing NT-3 or PDGF with no heparin pre-
sent. For Shh, only the 4:1 ratio produced a release rate that
was significantly different from that of the scaffolds con-
taining growth factor without heparin. Overall, the 4:1
peptide-to-heparin ratio resulted in maximum growth factor
retention inside the scaffolds for all growth factors tested.Determining optimal growth factor doses from the
delivery system for promoting ESNPC differentiation
into neurons and oligodendrocytes
Before the effects of controlled growth factor delivery on the
resulting cell phenotypes of the ESNPCs seeded inside were
examined, a set of control experiments was performed to
determine the effects of each of the delivery systemcomponents on differentiation and cell viability. For in
vitro differentiation studies, scaffolds were polymerized
containing the different components at the indicated
concentrations and all scaffolds were washed five times
over 24 h before cell seeding to remove unincorporated
components and to simulate the conditions of an in vivo
setting in which the unincorporated components would be
washed away. The effects of different delivery system
components on differentiation and viability after 14 days of
culture can be seen in Figs. 2A and 2B. When peptide alone or
peptide and heparin were incorporated into the scaffolds, a
decrease in astrocytes was observed. When heparin alone
was added to the scaffolds, a decrease in nestin (neural
progenitor) staining was observed in addition to the decrease
in the percentage of astrocytes. However, combining peptide
with heparin restored the nestin to levels similar to those of
the cultures in unmodified fibrin with no growth factors
present in the medium. The incorporation of the delivery
system components into the fibrin scaffold did not have any
effect on cell viability compared to the unmodified fibrin
scaffolds.
A series of various growth factor doses was delivered to
ESNPCs seeded inside fibrin scaffolds. Doses were selected
based on the previous studies conducted with growth factors
present in the culturemedium (Willerth et al., 2007a) and the
results of the release studies. The purpose of this study was to
determine the optimal dose for promoting differentiation of
neurons and oligodendrocytes from ESNPCs seeded inside
fibrin scaffolds containing the delivery system. As seen in Fig.
3A, all doses of NT-3 delivered resulted in a reduction of the
fraction of cells differentiating into astrocytes. Only the 125-
ng (417 ng/ml) dose produced an increase in the fraction of
neurons and neural progenitors obtained compared to the
group cultured in unmodified fibrin with no growth factors
present in the medium. Additionally, at this dose, an increase
in the fraction of cells differentiating into oligodendrocytes
was observed compared to the same dose of NT-3 when no
delivery system was present. Accordingly, the 125-ng dose of
NT-3 was selected for use in the combination growth factor
studies since it increased the fraction of cells that differ-
entiated into both neurons and oligodendrocytes.
Based on previous work, various PDGF doses ranging from
10 to 40 ng were delivered to ESNPCs seeded into fibrin
scaffolds, as seen in Fig. 3B. The 20-ng dose (66 ng/ml) of
PDGF promoted the highest level of differentiation of ESNPCs
igure 1 The effect of varying the peptide-to-heparin ratio in the affinity-based delivery system on growth factor release over a 14-day time course. (A) Release profile of NT-3 from
e delivery system. (B) Release profile of PDGF from the delivery system. (C) Release profile of Shh from the delivery system. #Pb0.05 versus all other groups. *Pb0.05 versus no
elivery system. Error bars indicate standard deviation.
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Figure 2 The effects of the affinity-based delivery system on ESNPC differentiation and survival inside fibrin scaffolds. (A)
Quantitative analysis of the effects of the different delivery system components on ESNPC differentiation inside fibrin scaffolds. (B)
Quantitative analysis of the effects of the different delivery system components on ESNPC viability inside fibrin scaffolds. *Pb0.05
compared to 14-day control cultures in unmodified fibrin with no growth factors present in the medium. Error bars indicate standard
deviation.
209Stem cell differentiation inside fibrin scaffoldsinto oligodendrocytes while reducing the fraction of cells
differentiating into astrocytes compared to the group cul-
tured in unmodified fibrin with no growth factors present in
the medium. For a 10-ng dose of PDGF (33 ng/ml), no diffe-
rences were observed compared to controls cultured in un-
modified fibrin with no growth factors present in the medium
and for the higher dose, only a decrease in the fraction of
cells staining positive for glial fibrillary acidic protein (GFAP)
was observed. When the 20-ng dose of PDGF was polymerized
into scaffolds with no delivery system present, only a de-
crease in the fraction of cells differentiating into astrocytes
was observed compared to the group cultured in unmodified
fibrin with no growth factors present in the medium.
When Shh was delivered from scaffolds containing the
delivery system, the 100-ng dose resulted in increases in the
fraction of cells differentiating into neurons and oligoden-drocytes produced while reducing the fraction of cells dif-
ferentiating into astrocytes compared to the cultures in
unmodified fibrin with no growth factors present in the
medium (Fig. 3C). The lowest Shh dose (50 ng total) produced
an increase only in the fraction of cells differentiating into
neurons while decreasing the fraction of cells differentiating
into astrocytes. However, no difference in the fraction of
cells differentiating into oligodendrocytes was observed
compared to the cultures in unmodified fibrin with no growth
factors present in the medium. A decrease in the fraction of
cells differentiating into astrocytes was the only difference
observed for both the highest dose of Shh delivered (150 ng)
and the 100-ng Shh dose with no delivery system present.
Based on these results, three different growth factor
combinations, NT-3 and PDGF, NT-3 and Shh, and NT-3, PDGF,
and Shh, were released from fibrin scaffolds both with and
Figure 3 The effects of controlled growth factor delivery on ESNPC differentiation inside fibrin scaffolds. (A) The effects of
controlled release of various NT-3 doses on ESNPC differentiation. (B) The effects of controlled release of various PDGF doses on ESNPC
differentiation. (C) The effects of controlled release of various Shh doses on ESNPC differentiation. Markers examined included SSEA-1
(undifferentiated ES cells), nestin (neural progenitors), Tuj1 (early neurons), O4 (oligodendrocytes), and GFAP (astrocytes). *Pb0.05
versus cultures in unmodified fibrin with no growth factors present in the medium. #Pb0.05 compared to optimal dose with no delivery
system present. Error bars indicate standard deviation.
210 S.M. Willerth et al.without the delivery system present, and the resulting diffe-
rentiation and viability were quantified as seen in Figs. 4A
and 4B. The optimal dose of each growth factor for pro-
moting ESNPC differentiation into neurons and oligodendro-
cytes that had been determined from the individual studies
was used in these combination studies. As seen in Fig. 4A,
no differences in the fraction of cells staining positive for
SSEA-1 was observed for any of the experimental groups, but
all experimental groups did exhibit a decrease in the fraction
of cells staining positive for GFAP compared to the group
cultured in unmodified fibrin scaffolds with no growth factor
present.All three growth factor combinations had significant
effects on the differentiation of ESNPCs compared to both
the group with no growth factor present and the scaffolds
containing the same doses of growth factors without a
delivery system. These three combinations all produced an
increase in the fraction of cells staining positive for nestin
and O4 compared to both the control group cultured in
unmodified fibrin scaffolds with no growth factor present
and the control group consisting of the same growth factor
doses with no delivery system. As mentioned before, the
control cultures without a delivery system are important to
show that the delivery system is retaining more growth
211Stem cell differentiation inside fibrin scaffoldsfactor as well as presenting it in a biologically active manner.
Controlled delivery of certain growth factor combinations
(the dual combination of NT-3 and PDGF or the triple
combination of NT-3, PDGF, and Shh) increased the fraction
of cells differentiating into neurons compared to both the
group with no growth factor present and the group consisting
of the same growth factor doses with no delivery system.
Controlled delivery of NT-3 and Shh increased only the
fraction of cells differentiating into neurons compared to
the group with no growth factor present. Additionally,
controlled delivery of NT-3 and PDGF also produced an
increase in the fraction of cells differentiating into neurons
compared to the controlled delivery of the other two growth
factor combinations tested, making this combination (NT-3
and PDGF) most effective for achieving the desired goal of
promoting differentiation of ESNPCs into neurons and
oligodendrocytes.
To confirm the results observed using fluorescence-acti-
vated cell sorting (FACS), real-time reverse transcriptase-
polymerase chain reaction (RT-PCR) was used to examine the
expression levels of four different markers for these cell
phenotypes, including Sox2 (neural progenitors), microtubule-
associated protein-2 (Map2; early neurons), platelet-derived
growth factor α receptor (PDGFαR; early oligodendrocytes),
and vimentin (astrocytes). Figure 4B shows the results of
the real-time RT-PCR performed to confirm the effects of
controlled delivery of NT-3 and PDGF compared to unmodi-
fied fibrin scaffolds and scaffolds containing NT-3 and PDGF
with no delivery system present. For the Sox2 marker, no
statistical differences were observed between groups.
Increases in the expression levels of Map2 and PDGFαR
compared to the unmodified fibrin scaffolds were observed
only for the group cultured in the scaffolds containing the
delivery system with NT-3 and PDGF. Both groups treated
with NT-3 and PDGF, both in the presence and in the absence
of delivery system, showed a decrease in the expression of
vimentin compared to the group cultured in unmodified
fibrin with no growth factors present in the medium. Figure
4C shows the effects of the various growth factor combina-
tions on cell viability. All growth factor combinations that
contained PDGF (both in presence and in the absence of the
delivery system) promoted an increase in cell viability com-
pared to the group with no growth factor present.Discussion
To produce an engineered tissue as a treatment for SCI,
delivery conditions and appropriate growth factor dosing for
promoting ESNPC differentiation into neurons and oligo-
dendrocytes were determined, as both of these cell types
could potentially contribute to functional recovery after SCI.
Neurons could help to restore the circuitry disrupted after
injury, allowing for reinnervation (Lee et al., 2007). Oli-
godendrocytes could restore the myelination of the spared
axons present at and around the injury site and such oligo-
dendrocyte replacement strategies have been shown to pro-
mote functional recovery in animal models of SCI (Keirstead
et al., 2005; Liu et al., 2000; Nistor et al., 2005). Addi-
tionally, minimizing astrocyte production was important, as
they could contribute to the glial scar and inhibit regenera-
tion (Fawcett and Asher, 1999).Release studies determined the appropriate delivery
system conditions needed to retain the maximum amount
of growth factor using the affinity-based delivery system.
The release studies were performed in the absence of cells to
quantify the amount of growth factor passively released over
time. In the in vitro culture system and in vivo, the remaining
growth factor is actively released from the scaffolds when
cells activate plasmin, which enzymatically degrades the
scaffold. In the in vitro culture system, the growth factors
can act upon the ESNPCs seeded inside the scaffolds, and in
vivo, the growth factors can be released by both the ESNPCs
and the surviving cells that remained after the injury.
Two different heparin concentrations were tested in the
context of the delivery system and the 4:1 ratio resulted in
maximum growth factor retention for all growth factors
tested. These results suggest that the increase in heparin
concentration provided more binding sites to retain the
growth factors inside the scaffold. For the 4:1 peptide-to-
heparin ratio, there is an∼1300-1700 times excess of binding
sites (heparin molecules) per growth factor, while the 40:1
ratio yields only ∼130-170 times excess of binding sites
(Table 1).
Table 1 shows the estimated fraction of growth factor
bound at equilibrium calculated from the dissociation
constants for each growth factor. The release rates of the
growth factors correlate with the estimated bound fraction
at equilibrium. The affinity-based delivery system was pre-
dicted to retain more PDGF and NT-3 than Shh at equilibrium.
This trend was observed in the release studies with the 4:1
ratio, which was confirmed by the 14-day release studies.
For NT-3 and PDGF, the delivery system retained different
amounts of growth factor depending on the peptide-to-
heparin ratio. The pattern of growth factor release was
consistent with previously published release studies of NT-3
and PDGF-BB, a different PDGF isoform (Taylor et al., 2004;
Thomopoulos et al., 2007). Only the 4:1 ratio retained Shh
inside the scaffolds. Shh had never been tested previously
with the affinity-based delivery system, but it has been
reported to have a high affinity for heparin (Rubin et al.,
2002; Zhang et al., 2007). The quick release of Shh could
potentially be due to repulsive interactions between Shh and
the scaffold itself.
An initial burst of growth factor release was observed over
the first 24 h. In an in vivo setting, this unbound growth
factor would be washed away from the scaffold by cere-
brospinal fluid present at the injury site. To account for this
effect, all scaffolds were washed five times before cell
seeding and the addition of the second scaffold layer. Diffe-
rent effects on ESNPC differentiation were observed when
the same growth factor dose was polymerized inside the
scaffolds in the presence of delivery system compared to
when no delivery system was present.
It is also important to consider the effects of the delivery
system on the differentiation of ESNPCs, as bioactive pep-
tides have been previously used to promote differentiation
of neural progenitors seeded on nanofibers (Silva et al.,
2004). The presence of peptide and heparin, both individu-
ally and in combination, reduced the fraction of ESNPCs that
differentiated into astrocytes. The reduction in the fraction
of cells that differentiated into astrocytes was observed for
all of the delivery system groups except when it was used to
delivery 10 ng total of PDGF, suggesting that the presence of
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213Stem cell differentiation inside fibrin scaffoldsgrowth factor does not interfere with this beneficial effect.
The presence of heparin alone decreased the fraction of
neural progenitors present, but this decrease was not ob-
served when both peptide and heparin were present,
suggesting that the peptide may help maintain nestin ex-
pression. When looking at the effects of the growth factors
on ESNPC differentiation, it is important to view the results
in the context of these control experiments. For other tissue-
engineering applications, it will be important to run similar
control experiments to ensure these components do not
interfere with the desired stem differentiation.
For each of the growth factors tested, a range of con-
centrations was selected by combining the results of the
release studies and previous studies that looked at the
effects of growth factors in the culture medium on ESNPC
differentiation inside fibrin scaffolds (Willerth et al., 2007a).
Controlled delivery of a 125-ng dose (417 ng/ml) from the
affinity-based delivery system produced neuron and oligo-
dendrocyte differentiation comparable to 25 ng/ml NT-3 in
the media. Soluble NT-3 has also been shown to promote the
differentiation of human ES cells into neurons in three-
dimensional settings, suggesting these scaffolds might also
be useful for human ES cell lines (Levenberg et al., 2005). NT-
3 also promotes the survival of oligodendrocyte precursors
(Kumar et al., 1998), which could potentially explain the
increase in O4 staining observed with controlled delivery of
the optimal dose (100 ng NT-3) with the delivery system.
Controlled delivery of NT-3 also produced an increase in the
percentage of cells staining positive for nestin, which could
potentially be due to the delivery system, as this effect
was not observed in the previous studies with NT-3 in the
medium.
From our previous work, the controlled release dose of
PDGF (20 ng total) corresponds to between 2 and 10 ng/ml
soluble PDGF and replicates the benefits of both doses,
which included an increase in the fraction of cells differ-
entiating into oligodendrocytes and a decrease in the frac-
tion of cells differentiating into astrocytes. These results are
consistent with other studies that have demonstrated PDGF's
role in promoting oligodendrocyte development (Calver et
al., 1998).
Controlled delivery of 100 ng of Shh produced similar
ESNPC differentiation to both 10 and 25 ng/ml Shh in the
medium. The increase in neuronal differentiation was ex-
pected, as many studies have demonstrated that Shh com-
bined with retinoic acid promotes the differentiation of ES
cells into motor neurons (Dutton et al., 1999; Lee et al.,
2007; Li et al., 2005; Miles et al., 2004; Soundararajan et al.,
2006, 2007). Shh also plays important roles in promoting
oligodendrocyte differentiation (Danesin et al., 2006; Oh et
al., 2005). The poor retention of Shh by the affinity-basedFigure 4 The effects of controlled delivery of growth factor co
scaffolds. (A) Quantitative analysis of the effects of the various grow
culture. Markers examined included SSEA-1 (undifferentiated ES
(oligodendrocytes), and GFAP (astrocytes). (B) Real-time RT-PCR a
scaffolds. Markers examined included Sox2 (neural progenitors), mi
derived growth factor α receptor (PDGFαR; early oligodendrocytes), a
of the various growth factor combinations on ESNPC survival after 1
fibrin with no growth factors present in the medium. #PN0.05 versus s
+Pb0.05 versus all other groups. Error bars indicate standard deviatdelivery system required polymerizing high doses of Shh into
the scaffolds to promote differentiation, and more effective
retention of Shh by an affinity-based delivery system might
be obtained by using different scaffold material.
Controlled delivery of all three growth factor combina-
tions produced significant changes compared to both unmo-
dified fibrin scaffolds with no growth factors present in the
medium and scaffolds containing the same growth factor
combinations with no delivery system. The main difference
between the three combinations tested was in the fraction of
cells differentiating into neurons. The combination of NT-3
and PDGF produced the largest fraction of cells differentiat-
ing into neurons compared to all the groups tested, making it
the optimal combination for further testing in the context of
an in vivo model of SCI. This result was also confirmed using
real-time RT-PCR analysis with increases in the expression
levels of Map2 and PDGFaR and a decrease in vimentin ex-
pression levels compared to the cultures in unmodified fibrin
scaffolds with no growth factors present.
These results are consistent with other literature that has
shown different situations in which combining NT-3 with
PDGF produces additive effects. Previous studies have shown
that this combination promotes the survival of Schwann cell
precursors and remyelination in rodent models of multiple
sclerosis, suggesting that their signaling pathways may share
an intermediate that produces these additional benefits
(Fressinaud, 2005; Lobsiger et al., 2000). Also, the inclusion
of PDGF in combination with other growth factors produced
an increase in cell viability. This increase in viability may
increase the survival rate of the transplanted cells in vivo.
This study has produced an engineered neural tissue
consisting of a fibrin scaffold containing an affinity-based
delivery system, growth factors, and ESNPCs ready for in vivo
testing as a potential treatment for SCI. The growth factor
delivery system and concentration were optimized to pro-
mote the differentiation of the cells seeded within these
scaffolds into neurons and oligodendrocytes and to increase
cell viability. The concentrations found in this study for
promoting the differentiation of ESNPCs into these cell phe-
notypes can be easily translated to other materials with
known release properties for in vivo SCI applications. Such a
strategy can be extended to generate replacements for other
types of damaged tissues. Finally, this affinity-based delivery
system could also be used to study signaling events during
development. Its ability to mimic the extracellular matrix
and present growth factors in a controlled manner allows for
the reproduction of signals present during development in an
in vitro setting. Thus, this delivery system allows for
generation of tissue-engineered scaffolds as well as provid-
ing an in vitro system for studying the development biology
of stem cells.mbinations on ESNPC differentiation and survival inside fibrin
th factor combinations on ESNPC differentiation after 14 days of
cells), nestin (neural progenitors), Tuj1 (early neurons), O4
nalysis to confirm FACS results after 7 days of culture inside
crotubule-associated protein-2 (Map2; early neurons), platelet-
nd vimentin (astrocytes). (C) Quantitative analysis of the effects
4 days of culture. *Pb0.05 versus control cultures in unmodified
ame growth factor combination with no delivery system present.
ion.
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215Stem cell differentiation inside fibrin scaffoldsMaterials and methods
All materials were purchased from Sigma-Aldrich unless
otherwise noted.
Preparation of fibrin scaffolds containing the
biomimetic delivery system
Plasminogen-free fibrinogen (Calbiochem) obtained from
human plasma was dissolved in Tris-buffered saline (TBS; pH
7.4) for 2 h at 37 °C. Sterile fibrinogen solutions were pre-
pared as previously described (Willerth et al., 2007b). Fibrin
scaffolds (10 mg/ml) were polymerized under conditions
previously determined be optimal for ES cell culture (Will-
erth et al., 2006). The affinity-based delivery system (Fig. 5)
consists of three components: a bidomain peptide, heparin,
and growth factor. The peptide contains a Factor XIIIa
substrate derived from α2-plasmin inhibitor (Ichinose et al.,
1983), allowing it to be covalently cross-linked into the fibrin
scaffold, and a heparin-binding domain derived from anti-
thrombin III (Tyler-Cross et al., 1994), which binds heparin
noncovalently and retains it inside the fibrin scaffold. The
heparin can in turn bind growth factors with an affinity for
heparin and retain them inside the scaffold. Thus these two
reversible reactions (peptide binding to heparin and heparin
binding to growth factor) allow the delivery system to retain
growth factors noncovalently inside the fibrin scaffolds. At
equilibrium, five different species are present inside the
scaffold, including unbound heparin, unbound growth factor,
heparin-growth factor complexes, heparin bound to the
immobilized peptide, and heparin-growth factor complexes
that are bound to the peptide.
The goal of using this delivery system is to maximize the
fraction of heparin-growth factor complexes that are bound
to the peptide inside the fibrin scaffold. For promoting
differentiation of ESNPCs, it is important to maximize the
amount of growth factor retained inside the scaffold to
ensure retention in an in vivo setting. Changing the
concentration of heparin present affects the amount of
growth factor retained inside the scaffold by shifting the
chemical equilibrium of the system. In the reversible
reaction, when heparin and growth factor bind to form a
complex, adding excess unbound heparin should cause
increased formation of heparin-growth factor complexes at
equilibrium according to LeChatlier's principle. These com-
plexes can in turn bind noncovalently to the immobilized
peptide, becoming immobilized inside the scaffold. Differ-
ent heparin concentrations will result in different amounts
of heparin-growth factor complexes being formed, affecting
the amount of heparin-growth factor complexes that can
bind to the immobilized peptide at equilibrium. In this
manner, the amount of heparin present affects the rate at
which growth factor is released from the scaffolds. Previous
work from our lab has demonstrated that 4:1 and 40:1Figure 5 Diagrams showing the affinity-based delivery system and
system. The bidomain peptide becomes covalently cross-linked into t
heparin-binding domain, allowing heparin to be noncovalently retai
the growth factor, causing it to remain in the scaffold. (B) Schema
seeding and culture inside the fibrin scaffolds.peptide-to-heparin ratios produce sustained growth factor
release from fibrin scaffolds (Taylor et al., 2004; Wood and
Sakiyama-Elbert, 2008).
To produce the components needed for the delivery sys-
tem, the bidomain peptide (amino acid sequence: (AcG)
NQEQVSPK(βA)FAKLAARLYRKA, transglutaminase substrate
indicated by italics) was synthesized using standard Fmoc
chemistry (amino acids from EMD Biosciences and peptide
synthesis solvents from Applied Biosystems) and purified
using reverse-phase C18 chromatography, with the peptide
sequence being confirmed using matrix-assisted laser deso-
rption ionization mass spectroscopy as previously described
(Willerth et al., 2007b; Wood and Sakiyama-Elbert, 2008).
Sterile porcine heparin solutions (average molecular weight
18 kDa; concentrations 6.25 and 62.5 μM) were prepared and
the following growth factors were delivered using this
system: NT-3 (Peprotech), PDGF-AA (R and D Systems), and
Shh (R and D Systems). These components were added at the
indicated concentrations during the fibrin polymerization
process to ensure incorporation into the scaffolds.
Characterization of controlled growth factor
release from fibrin scaffolds
Fibrin scaffolds (400 μl) were polymerized to contain 0.25
mM bidomain peptide, 100 ng/ml of growth factor (40 ng
total), and varying concentrations of heparin. Control scaf-
folds contained no heparin, while the experimental scaffolds
contained either 6.25 or 62.5 μM heparin, corresponding
to 40:1 and 4:1 peptide-to-heparin ratios. Two different
peptide-to-heparin ratios were tested to determine which
ratio retains the maximum amount of growth factor inside
the scaffold. The peptide-to-heparin ratios and the heparin-
to-growth factor ratios tested are listed in Table 1.
These acellular scaffolds were washed five times over the
first 24 h with 1 ml of TBS containing 2k bovine serum
albumin (BSA) followed by once a day for the next 13 days,
resulting in a 14-day time course. Each wash was collected in
a silanized tube and stored at −20 °C. After the end of the
study, the remaining growth factor was released from the
scaffold using extraction buffer (phosphate-buffered saline
containing 10 mg/ml heparin, 2 M NaCl, 1k BSA, 0.01k
Triton-X, pH 7.4) as previously described (Willerth et al.,
2007b; Wood and Sakiyama-Elbert, 2008). The amount of
NT-3 and Shh present in the washes and scaffolds was
quantified using ELISA kits (R and D Systems). To quantify the
amount of PDGF present, a monoclonal α-PDGF-AA antibody
(clone MAB1055; R and D Systems) was used as the capture
antibody and a biotinylated α-PDGF-AA antibody (clone
BAF1055) served as the detection antibody. Absorbance
readings at 450 nm were measured using a 96-well plate
reader (Multiskan RC Labsystems). The experimental wells
were compared to a concentration curve of known standards
to determine the quantity of growth factor present.cell culture process. (A) Schematic of the affinity-based delivery
he fibrin scaffold during polymerization. This peptide contains a
ned inside the scaffold. The heparin in turn noncovalently binds
tic of the process for producing embryoid bodies, followed by
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RW4 mouse ES cells were cultured on gelatin-coated plates
using complete medium (Dulbecco's modified Eagle medium
containing 10k fetal bovine serum, 10k newborn calf serum,
and 0.3 M nucleoside mix, all from Invitrogen except the
nucleosides, which were from Sigma) containing 1000 U/ml
leukemia inhibitory factor (LIF) and 10-4 M β-mercaptoethanol
(BME) as described previously (Willerth et al., 2006, 2007a).
Undifferentiated ES cells were induced to form embryoid
bodies (EBs) containing ESNPCs using the 4−/4+ retinoic acid
treatment protocol before being seeded onto the scaffolds
(Bain et al., 1995). The cells were cultured in complete me-
dium without LIF or BME for the first 4 days followed by an
additional 4 days of culture in complete medium containing
100 nM retinoic acid. The medium was changed every other
day during this process. The 4−/4+ retinoic acid treatment
protocol produces a cell population consisting of immature
neural progenitors (Willerth et al., 2007a). Of these cells,
61F6k stain positive for the SSEA-1 marker, which is
expressed by undifferentiated mouse ES cells, and 71F6k
of these cells stain positive for nestin, which is a neural
progenitor marker. These cells did not stain positive for any of
the mature neural cell markers, including β-tubulin III (early
neurons), O4 (oligodendrocytes), and GFAP (astrocytes).
For studying the effects of controlled growth factor
release, 300 μl of scaffold containing delivery system and
growth factors was added into each well of a 24-well plate
(Corning) and allowed to polymerize for 1 h at 37 °C. These
scaffolds were then washed five times with 1 ml of TBS over
the next 24 h, with each wash being applied for at least 2 h
to remove unincorporated delivery system components.
Following aspiration of the final wash, an individual EB
was placed on each scaffold and a second layer of scaffold
(100 μl) without delivery system was then added to
surround each EB. After an additional hour of incubation
at 37 °C, 1 ml of complete medium was added and the cells
were cultured in scaffold for 14 days, with the medium
being changed to neural basal medium containing B27
supplement (both from Invitrogen) on day 3 as previously
described (Willerth et al., 2006, 2007a). A schematic of this
process is shown in Fig. 5B.
Fluorescence-activated cell sorting
After 14 days of culture, themediumwas aspirated from each
scaffold, followed by a wash with phosphate-buffered saline
(PBS; pH 7.4). Cells were dissociated using trypsinization and
manually removed from the scaffolds and then resuspended
in PBS. The cells were then stained and sorted as previously
described (Willerth et al., 2007a). For cell phenotype ana-
lysis, cells were stained for the following markers: stage-
specific embryonic antigen 1 marker (SSEA-1; undifferen-
tiated mouse ES cells; 1:25; Chemicon), nestin (neural pre-
cursors; 1:100; Chemicon), β-tubulin III (Tuj1; early neurons;
1:1000; Covance), O4 marker (1:100; oligodendrocytes;
Chemicon), and GFAP (astrocytes; 1:40; Immunostar). Spe-
cies-specific secondary antibodies (AlexaFluor 488; Invitro-
gen) were used to detect the primary antibodies. For cell-
surface markers (SSEA-1 and O4), live cells were blocked
using PBS containing 5k normal goat serum (NGS) followed by1-h incubations with primary and secondary antibody. For
intracellular markers (nestin, Tuj1, and GFAP), cells were
fixed with 1k paraformaldehyde, permeabilized with 0.5k
saponin solution, and blocked with 5k NGS solution. These
cells were then incubated with primary and secondary
antibodies for 30 min each. Cells stained with secondary
antibody only were used to eliminate nonspecific background
secondary antibody staining. A more stringent control would
have been to use an isotype control primary antibody to
ensure the specificity of the staining. For quantitative ana-
lysis of cell viability, cells were stained using the Live/Dead
Viability/Cytotoxicity kit (Invitrogen) as previously described
(Willerth et al., 2007a). The cells were incubated with PBS
solutions containing 0.1 μM calcein AM and 16 μM ethidium
homodimer for 30 min. Cellular fluorescence was detected
using a FACSCalibur flow cytometer (Becton-Dickinson) and
analysis was performed using CellQuest software (Becton-
Dickinson). Representative plots showing the fluorescence
for the different control and experimental groups are shown
for the cultures seeded inside unmodified fibrin scaffolds
with no growth factors present and the cultures seeded inside
scaffolds containing the delivery system along with PDGF and
NT-3 in Supplementary Figs. 1 and 2.
Quantitative real-time RT-PCR
To confirm the results observed using FACS, quantitative
real-time RT-PCR was used to examine the expression levels
of markers for different cell phenotypes for three different
groups, including EBs cultured in unmodified fibrin, in
scaffolds containing NT-3 and PDGF with no delivery system
present, and in scaffolds containing NT-3 and PDGF with a
delivery system. Real-time RT-PCR was used to examine the
expression of the following four markers: Sox2 (neural
progenitors), Map2 (early neurons), PDGFαR (early oligoden-
drocytes), and vimentin (astrocytes).
To obtain RNA for real-time RT-PCR analysis, the cells were
cultured inside scaffolds for 7 days. An earlier time point was
chosen because mRNA upregulation often occurs before
changes in protein expression are observed. Cells were then
isolated from the scaffolds using trypsin as described above
and the resulting cells were lysed using Buffer RLT (Qiagen).
These lysates were homogenized using a Qiashredder kit and
RNAwas then isolated using an RNEasy kit (both fromQiagen).
From the isolated RNA, cDNA was synthesized using the
Quantitech reverse transcription kit (Qiagen) according to
the manufacturer's instructions. Using the Quantitech SYBR
Green PCR Mastermix (Qiagen) combined with gene-specific
QuantiTect primer assays, quantitative real-time PCR was
performed using an Applied Biosystems 7000 real-time PCR
system using the following PCR cycle: 50 °C for 2 min, 95 °C
for 10min, followed by 40 cycles of 95 °C for 15 s, 55 °C for 30
s, 72 °C for 30 s, with fluorescent signal detected at 72 °C.
Target genes were normalized to β-actin expression to
account for variations in cDNA concentration between
samples. The differences in gene expression levels were
calculated using the comparative DCt method, which allows
for determining relative expression of RNA between two
samples. In this method, the crossover threshold (Ct) refers to
the cycle number when the fluorescence released by the PCR
reaction begins to increase exponentially. The difference
between relative Ct values for each sample was used to
217Stem cell differentiation inside fibrin scaffoldsestimate the fold difference in expression between samples
compared to unmodified fibrin scaffolds.
Statistical analysis
For the release studies, four independent release experiments
(one scaffold per experiment) were analyzed for each set of
delivery system conditions. For cell phenotype analysis, three
independent experiments consisting of one 24-well plate
containing fibrin scaffolds with EB cultures per experiment
were performed for each condition tested. For cell viability
analysis, three independent experiments analyzing 6 wells
containing fibrin scaffolds seeded with EB cultures were
performed. These conditions provided enough cells (5000 per
sort for each individual experiment) to perform FACS and
statistical analysis on the outcomes. For real-time RT-PCR
analysis, three independent experiments analyzing 6 wells
containing fibrin scaffolds seeded with EB cultures were
performed. Analysis of variance applying Scheffé post hoc
tests was used to compare experimental and control groups.
Significance was considered to be at the Pb0.05 level.
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